Travere Therapeutics, Inc.
TVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001438533
In the last 90 days, Travere Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 320 institutions reported holding it in 13F filings for Q2 2026, worth $5.98B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Travere Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 197
- +20 vs. Q3 2024
- Shares held
- 95.1M
- +12.3M (+14.9%) vs. Q3 2024
- Total value
- $1.66B
- +$498.7M (+43.1%) vs. Q3 2024
- New holders
- 48
- 74 more added
- Sold out
- 28
- 53 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 320 | $5.98B |
| Q1 2026 | 261 | $3.01B |
| Q4 2025 | 278 | $3.90B |
| Q3 2025 | 238 | $2.41B |
| Q2 2025 | 213 | $1.49B |
| Q1 2025 | 218 | $1.77B |
| Q4 2024 | 197 | $1.66B |
| Q3 2024 | 178 | $1.16B |
| Q2 2024 | 174 | $723.4M |
| Q1 2024 | 175 | $677.4M |
| Q4 2023 | 165 | $769.6M |
| Q3 2023 | 169 | $737.2M |
| Q2 2023 | 169 | $1.27B |
| Q1 2023 | 175 | $1.89B |
| Q4 2022 | 155 | $1.53B |
| Q3 2022 | 171 | $1.72B |
| Q2 2022 | 171 | $1.68B |
| Q1 2022 | 169 | $1.79B |
| Q4 2021 | 169 | $2.04B |
| Q3 2021 | 148 | $1.48B |
| Q2 2021 | 136 | $900.8M |
| Q1 2021 | 150 | $1.56B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Travere Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HighVista Strategies LLC | 0 | $0 | 0.00% | −147,233−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −125,000−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −111,341−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −103,933−100.0% | Sold out |
| TD Asset Management Inc | 0 | $0 | 0.00% | −71,800−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −62,245−100.0% | Sold out |
| Oppenheimer & Co Inc | 0 | $0 | 0.00% | −48,139−100.0% | Sold out |
| Hennion & Walsh Asset Management, Inc. | 0 | $0 | 0.00% | −36,604−100.0% | Sold out |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −35,748−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −29,125−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −28,415−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −28,217−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −21,500−100.0% | Sold out |
| Acuta Capital Partners, LLC | 0 | $0 | 0.00% | −19,000−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −17,688−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −16,452−100.0% | Sold out |
| Cerity Partners LLC | 0 | $0 | 0.00% | −13,748−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −13,667−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −11,508−100.0% | Sold out |
| Martingale Asset Management L P | 0 | $0 | 0.00% | −11,304−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −4,037−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −900−100.0% | Sold out |
| Elequin Capital LP | 0 | $0 | 0.00% | −462−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −458−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −479−100.0% | Sold out |
| Raymond James & Associates | – | – | – | – | Not filed |